CG-BM1 / Guangzhou Cellgenes Biotechnology - LARVOL DELTA

Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients (clinicaltrials.gov) - P1/2 | N=90 | Completed | Sponsor: Sun Yat-sen University | Recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ May 2026 | Trial primary completion date: Oct 2025 ➔ Mar 2026

Trial completion • Trial completion date • Trial primary completion date • Hepatology • Liver Failure

Safety and Efficacy of Allogeneic Bone Marrow MSCs in Ankylosing Spondylitis (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Eighth Affiliated Hospital, Sun Yat-sen University

New P1 trial • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and safety of Human Bone Marrow Derived Mesenchymal in Patients with pre-acute-on-chronic liver failure (ChiCTR) - P=N/A | N=66 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University

New trial • Hepatology • Liver Failure